Maija Radzina is the President of Latvian Radiology Society and Consultant and Researcher at Paula Stradina clinical university hospital.She is the Member of Educational Commitee,Occupational Court at Latvian Medical Association.

Vascular, Neuro, Abdominal, Musculoskeletal, Emergency Radiology and Contrast enhanced ultrasound

Rupan Sanyal is an Associate Professor and Diagnostic Radiologist at University of Alabama. He has been the editorial board member of American Journal of Roentgenology, Abdominal Imaging etc. and has authored 9 articles. Dr. Sanyal has received many prestigious awards including Silver Medal for the ARRS Annual Meeting Educational Exhibit “Technique, indications and quantification of secretin enhanced MRCP(2010), Certificate of Merit for the ARRS Annual Meeting Electronic Exhibit “Abdominal MR in the sick patient: Basic steps to improve image quality(2011), Bronze Medal for the ARRS Annual Meeting Educational Exhibit “Liver Transplantation and Hepatocellular Carcinoma Imaging Jargon Explained: What Does a Radiologist Need to Know(2015).

Use of advanced imaging modalities including MR, CT and US in the evaluation of various abdominal pathologies

Dr. Rathan M. Subramaniam is an Associate Professor in the Johns Hopkins Medicine Division of Nuclear Medicine within the Department of Radiology and Radiological Science. He also has appointments in the Department of Otolaryngology-Head and Neck Surgery and the Department of Oncology. An internationally recognized expert in quantitative molecular imaging with positron emission tomography (PET) and computed tomography (CT), Dr. Subramaniam specializes in diagnostic radiology.He has published nearly 80 peer-reviewed articles, co-edited Novel Imaging Techniques in Neurodegenerative and Movement Disorders, An Issue of PET Clinics, 1e (The Clinics: Radiology) and authored PET/CT and PET/MRI in Oncology: A Practical Guide.A Fellow of the Royal Australian and New Zealand College of Radiologists, Dr. Subramaniam is American Board of Radiology-certified in neuroradiology and diagnostic radiology.

Cancer, Neuroimaging, and Health policy and management.

Prof Kalevi Kairemo graduated with a MSc(Eng) degree from Helsinki University of Technology in 1980 before undertaking medical training at the University of Helsinki. He undertook specialist training in Clinical Chemistry, Nuclear Medicine, Health Care Administration and Clinical Pharmacology at Helsinki University Central Hospital and then a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center from 1989-93. Prof Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). Since 2009, he has worked at the Docrates Cancer Center in Helsinki. Recently he received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). He has authored more than 200 original peer-reviewed publications.

FDG-PET and PET/CT

Michael Friebe has been involved in diagnostic imaging and image guided therapeutic products and services, as founder / innovator / CEO investor, and scientist. Dr. Friebe currently is a Board Member of two startup R&D companies, as well as investment partner of a medical technology startup-fund. Dr. Friebe is an affiliated professor with the chair for Computer Aided Medical Procedures (CAMP) at TU München, and full professor of Image Guided Therapies at the Ottovon- Guericke-University in Magdeburg, Germany. He is listed inventor of more than 60 patent applications and the author of numerous papers.

Diagnostic imaging and Image guided therapeutics

Chun Li, Ph.D. is a professor in the Department of Cancer Systems Imaging at The University of Texas M. D. Anderson Cancer Center. Dr. Li earned his doctorate in chemistry at Rutgers-The State University of New Jersey hn. His undergraduate degree was obtained from Peking University, Beijing, China. Research in Dr. Li’s laboratory is primarily focused on two areas: 1) Develop targeted imaging probes for noninvasive characterization of molecular events associated with tumor progression and regression. Multiple imaging modalities, including PET, SPETC, MRI and optical imaging are used to acquire complementary data with increased sensitivity and selectivity for early tumor detection, tumor-marker profiling and the monitoring of early treatment responses. 2) Develop novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents to the disease sites. Nanometric drug carriers are designed for selective delivery of anticancer agents to the tumor to maximize their therapeutic efficacy and minimize their toxic side effects to normal tissue. The long-term goal of Dr. Li’s laboratory is to apply the “seek and treat” strategy in the development of targeted imaging/ therapeutic (theranostic) agents that will eventually be translated to the clinic to improve the management of cancer through early tumor detection and individualized therapy. A polymer-drug conjugate (PG-TXL) originated from his laboratory has advanced into clinical phase III trials studies. Dr. Li has more than 140 papers published in peer-reviewed journals, 28 patents (4 of which have been licensed), 1 edited book, and 14 book chapters.

Novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents to the disease sites.

Dr Marc Griffiths is an Associate Dean within the Faculty of Health and Applied Sciences at the University of the West of England, Bristol and completed his Professional Doctorate in 2014. His Professional Doctorate evaluated the impact of the introduction of new hybrid imaging technology on the nuclear medicine workforce. He has published a number of papers in peer reviewed journals related to the development of the nuclear medicine workforce and associated factors, including mentorship, education and training competencies. Marc works closely with education commissioners and is involved in healthcare workforce planning and scenario modelling.

Hybrid imaging technology

With a prior MD, upon receiving his PhD in 1995, Yicheng Ni initiated and heads a Theragnostic Lab at KU Leuven, Belgium. Being currently titled with full professor and Bayer Lecture Chair, he has published over 200 SCI journal papers, book chapters and patents, trained numerous PhD students, served as editor or reviewer in academic journals, and received tens of honors including Herbert M Stauffer Award (1993) and Elliott Lasser Award (2009). His academic career has been marked with innovative, translational, cost-effective and longstanding research. OncoCiDia introduced here presents one of his multiple inventions.

Imaging and contrast media research

Since 2007 Professor and Chair of the Department of Radiation Oncology, University Medical Center Freiburg, Germany; 2006-2007 Harvard Medical School, Massachusetts General Hospital, Department of RadiationOncology, Proton Therapy Center, Boston, USA; 2000 - 2006 Assistant Medical Director, Department of Radiation Oncology, Rechts der Isar Hospital, Technical University, Munich, Germany ; 2003 Postdoctoral lecture qualification, Department of Radiation Oncology, Rechts der Isar Hospital, Technical University, Munich, Germany; 2000 Board Certification Radiation Oncology

Biological imaging for radiation therapy planning and monitoring High precision radiation therapy

Carmen I. Bigles is CEO of Coquí RadioPharmaceuticals, Corp. a company with the goal of establishing a medical radioisotope production facility in the U.S. As co-owner of Caribbean Radiation Oncology Center, Bigles learned that many patients were being misdiagnosed due to a global shortage of Mo-99. Bigles sought to learn more about the Mo-99 industry and ultimately decided to establish a domestic source of the isotope. Bigles earned a bachelor’s degree in mathematics from Interamerican University in San Juan and subsequently her master’s degrees in architecture and suburban and town planning from the University of Miami.

Medical Isotope Company

Carmen I. Bigles is CEO of Coquí RadioPharmaceuticals, Corp. a company with the goal of establishing a medical radioisotope production facility in the U.S. As co-owner of Caribbean Radiation Oncology Center, Bigles learned that many patients were being misdiagnosed due to a global shortage of Mo-99. Bigles sought to learn more about the Mo-99 industry and ultimately decided to establish a domestic source of the isotope. Bigles earned a bachelor’s degree in mathematics from Interamerican University in San Juan and subsequently her master’s degrees in architecture and suburban and town planning from the University of Miami.

Medical Isotope Company

Since 2007 Professor and Chair of the Department of Radiation Oncology, University Medical Center Freiburg, Germany; 2006-2007 Harvard Medical School, Massachusetts General Hospital, Department of RadiationOncology, Proton Therapy Center, Boston, USA; 2000 - 2006 Assistant Medical Director, Department of Radiation Oncology, Rechts der Isar Hospital, Technical University, Munich, Germany ; 2003 Postdoctoral lecture qualification, Department of Radiation Oncology, Rechts der Isar Hospital, Technical University, Munich, Germany; 2000 Board Certification Radiation Oncology

Biological imaging for radiation therapy planning and monitoring High precision radiation therapy

Dr. Knopp has a long track record of developing and validating new imaging methodologies with a special interest in MRI, PET and safety. His scientific focus has been imaging of angiogenesis and response assessment. His current research focus is on functional and molecular hybrid imaging based assessment as well as validation of imaging methodologies as biomarkers. He has been extensively funded for developing, analyzing and performing imaging-based analysis to diagnose and assess therapies. With the initial funding of the Wright Center of Innovation in Biomedical Imaging, he has been able to build up an extensive infrastructure that provides state-of-the-art capabilities to perform advanced imaging studies as well as their analysis.

Biomedical Imaging

With a prior MD, upon receiving his PhD in 1995, Yicheng Ni initiated and heads a Theragnostic Lab at KU Leuven, Belgium. Being currently titled with full professor and Bayer Lecture Chair, he has published over 200 SCI journal papers, book chapters and patents, trained numerous PhD students, served as editor or reviewer in academic journals, and received tens of honors including Herbert M Stauffer Award (1993) and Elliott Lasser Award (2009). His academic career has been marked with innovative, translational, cost-effective and longstanding research. OncoCiDia introduced here presents one of his multiple inventions.

Imaging and contrast media research

Dr Marc Griffiths is an Associate Dean within the Faculty of Health and Applied Sciences at the University of the West of England, Bristol and completed his Professional Doctorate in 2014. His Professional Doctorate evaluated the impact of the introduction of new hybrid imaging technology on the nuclear medicine workforce. He has published a number of papers in peer reviewed journals related to the development of the nuclear medicine workforce and associated factors, including mentorship, education and training competencies. Marc works closely with education commissioners and is involved in healthcare workforce planning and scenario modelling.

Hybrid imaging technology

Chun Li, Ph.D. is a professor in the Department of Cancer Systems Imaging at The University of Texas M. D. Anderson Cancer Center. Dr. Li earned his doctorate in chemistry at Rutgers-The State University of New Jersey hn. His undergraduate degree was obtained from Peking University, Beijing, China. Research in Dr. Li’s laboratory is primarily focused on two areas: 1) Develop targeted imaging probes for noninvasive characterization of molecular events associated with tumor progression and regression. Multiple imaging modalities, including PET, SPETC, MRI and optical imaging are used to acquire complementary data with increased sensitivity and selectivity for early tumor detection, tumor-marker profiling and the monitoring of early treatment responses. 2) Develop novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents to the disease sites. Nanometric drug carriers are designed for selective delivery of anticancer agents to the tumor to maximize their therapeutic efficacy and minimize their toxic side effects to normal tissue. The long-term goal of Dr. Li’s laboratory is to apply the “seek and treat” strategy in the development of targeted imaging/ therapeutic (theranostic) agents that will eventually be translated to the clinic to improve the management of cancer through early tumor detection and individualized therapy. A polymer-drug conjugate (PG-TXL) originated from his laboratory has advanced into clinical phase III trials studies. Dr. Li has more than 140 papers published in peer-reviewed journals, 28 patents (4 of which have been licensed), 1 edited book, and 14 book chapters.

Novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents to the disease sites.

Michael Friebe has been involved in diagnostic imaging and image guided therapeutic products and services, as founder / innovator / CEO investor, and scientist. Dr. Friebe currently is a Board Member of two startup R&D companies, as well as investment partner of a medical technology startup-fund. Dr. Friebe is an affiliated professor with the chair for Computer Aided Medical Procedures (CAMP) at TU München, and full professor of Image Guided Therapies at the Ottovon- Guericke-University in Magdeburg, Germany. He is listed inventor of more than 60 patent applications and the author of numerous papers.

Diagnostic imaging and Image guided therapeutics

Prof Kalevi Kairemo graduated with a MSc(Eng) degree from Helsinki University of Technology in 1980 before undertaking medical training at the University of Helsinki. He undertook specialist training in Clinical Chemistry, Nuclear Medicine, Health Care Administration and Clinical Pharmacology at Helsinki University Central Hospital and then a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center from 1989-93. Prof Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). Since 2009, he has worked at the Docrates Cancer Center in Helsinki. Recently he received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). He has authored more than 200 original peer-reviewed publications.

FDG-PET and PET/CT

Dr. Rathan M. Subramaniam is an Associate Professor in the Johns Hopkins Medicine Division of Nuclear Medicine within the Department of Radiology and Radiological Science. He also has appointments in the Department of Otolaryngology-Head and Neck Surgery and the Department of Oncology. An internationally recognized expert in quantitative molecular imaging with positron emission tomography (PET) and computed tomography (CT), Dr. Subramaniam specializes in diagnostic radiology.He has published nearly 80 peer-reviewed articles, co-edited Novel Imaging Techniques in Neurodegenerative and Movement Disorders, An Issue of PET Clinics, 1e (The Clinics: Radiology) and authored PET/CT and PET/MRI in Oncology: A Practical Guide.A Fellow of the Royal Australian and New Zealand College of Radiologists, Dr. Subramaniam is American Board of Radiology-certified in neuroradiology and diagnostic radiology.

Cancer, Neuroimaging, and Health policy and management.

Rupan Sanyal is an Associate Professor and Diagnostic Radiologist at University of Alabama. He has been the editorial board member of American Journal of Roentgenology, Abdominal Imaging etc. and has authored 9 articles. Dr. Sanyal has received many prestigious awards including Silver Medal for the ARRS Annual Meeting Educational Exhibit “Technique, indications and quantification of secretin enhanced MRCP(2010), Certificate of Merit for the ARRS Annual Meeting Electronic Exhibit “Abdominal MR in the sick patient: Basic steps to improve image quality(2011), Bronze Medal for the ARRS Annual Meeting Educational Exhibit “Liver Transplantation and Hepatocellular Carcinoma Imaging Jargon Explained: What Does a Radiologist Need to Know(2015).

Use of advanced imaging modalities including MR, CT and US in the evaluation of various abdominal pathologies.

Maija Radzina is the President of Latvian Radiology Society and Consultant and Researcher at Paula Stradina clinical university hospital.She is the Member of Educational Commitee,Occupational Court at Latvian Medical Association.

Vascular, Neuro, Abdominal, Musculoskeletal, Emergency Radiology and Contrast enhanced ultrasound